We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on Merck (MRK) to $122 from $130 and keeps a Buy rating on the shares. The firm ...

Shares of Merck & Co. Inc. MRK shed 2.76% to $97.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and ...

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr.

Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytruda, with less than three years to go ...

Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...

Merck (MRK) stock in focus as the company eyes 2025 launch of subcutaneous Keytruda amid a looming patent cliff for its ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...